The study, published in Clinical Cancer Research in 2010, looked at which patients might respond to the drug, called figitumumab. Here’s the notice:
The article titled “Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition,” which was published in the September 15, 2010, issue of Clinical Cancer Research (1), is being retracted at the request of Pfizer, one of the study sponsors, following its investigation into the data from Study 1002, which was a phase II study designed to examine figitumumab, a humanized antibody to insulin growth factor I receptor, in combination with chemotherapy in non–small cell lung cancer.
While conducting database close-out activities, Pfizer became aware that the final data from Study 1002 differed from the results that had been previously reported. The primary efficacy results from the study were published in the Journal of Clinical Oncology (JCO) in May 2009, and the results of certain biomarker analyses performed in connection with it were published in the British Journal of Cancer (BJC) in January 2011 (2, 3). Pfizer provided both journals with new data, and both journals have retracted the affected articles.
These concerns, in combination with the issues that led to the retractions of the figitumumab articles published in JCO and BJC, have led Pfizer to conclude that the reported results from the figitumumab study are unreliable. Thus, Pfizer has requested a retraction of this article. A copy of this notice was sent to the authors prior to publication.
The paper has been cited 36 times, according to Thomson Scientific’s Web of Knowledge.
This is the third retraction involving figitumumab. The first was in the Journal of Clinical Oncology, and the second was in the British Journal of Cancer. The experimental drug, the company told us in 2012,
is a Pfizer-discovered monoclonal antibody that was developed for the treatment of various forms of cancer, including lung, prostate, breast and colorectal cancers and Ewing’s sarcoma.
The corresponding author of all of the studies is Antonio Gualberto, who left Pfizer in 2010 and was most recently at Brown University and Millennium Pharmaceuticals.
Hat tip: Rolf Degen